Table
1: Series with thoracoabdominal
and myocutaenous flaps used in primary closure after mastectomy.
|
Flap/ Author |
Number of cases |
Cases with necrosis |
Necrosis Rate |
|
Thoracoabdominal Flap |
|
|
|
|
Deo (2018) [38] |
72 |
8 |
11.1% total; 8.3% superficial; 2.7% Major |
|
Min [34] |
41 |
17 |
42.5% |
|
|
|
|
4,9% extensive necrosis |
|
Baroudi |
34 |
10 |
29.4% |
|
Buratani |
30 |
0 |
0 |
|
Vieira/ ITADE [36] |
23 |
9 |
34.8% tip necrosis 4.1% extensive necrosis |
|
Deo (2003) [35] |
22 |
2 |
9.1% |
|
Das |
20 |
1 |
5% |
|
Persichetti |
18 |
4 |
22.2% |
|
Kubo/ Romboid [63] |
14 |
2 |
14.3% |
|
Park-TE (medial pedicle) |
10 |
6 |
60.0% |
|
Park-TA (lateral pedicle) |
9 |
2 |
22.2% |
|
Martela |
8 |
0 |
0 |
|
Tai |
5 |
1 |
20.0% |
|
Lim |
3 |
0 |
0 |
|
|
|
|
|
|
Myocutaneos Flap |
|
|
|
|
Le Boudec/ LD [42] |
101 |
3 |
3% |
|
Apffelstaedt/ LD [43] |
83 |
14 (7 major) |
16.8% 8,4% major |
|
Salmon/ LD |
40 |
2 |
5.0% |
|
Munhoz/ LD |
25 |
2 |
8.0% |
|
Woo/ LD |
12 |
0 |
0% |
|
Amelung |
12 |
4 |
25% |
|
Micali/ LD |
8 |
3 |
37.5% |
|
|
|
|
|
|
Lee/ EOMF [40] |
75 |
9 |
12.0% |
|
Bogossian/ EOMF |
20 |
1 |
5% |
|
Gesson-Paute/ EOMF |
9 |
0 |
0% |
|
Cordoba/ EOMF |
13 |
1 |
7.7% |
|
Vieira/ MEOMF [39] |
17 |
12 |
70.5% |
|
|
|
|
|
|
Charanek/ VRAM [45] |
55 |
2 |
3.6% |
|
Lin/ TRAM [44] |
16 |
1 |
6.3% |
|
Mir/ TRAM-VRAM [41]* |
60 |
8 |
13.3% |
|
|
|
|
|
|
Mirza/ VRAM[46]** |
58 |
10 |
17.2% |
|
Daigeler/ VRAM[47]** |
78 |
10 |
12.8% |
Adapted from
Vieira et al. [36]. New
publications included [34, 38-43].
LD: Latissimus Dorsi; EOMF: External Oblique
Myocutaneous Flap; MEOMF: Modified EOMF; ITADE: Ipsilateral Thoracoabdominal
Dermofat flap.
*Reconstruction
for breast reconstruction for LABC; **Oncologic patients.